一个由抑制剂诱导的血管转化酶 (ACE) 抑制剂诱导的小肠血管的案例
Sarmad Pirzada1, Beebarg Raza1, Ali Abbas Mankani2
1Internal Medicine, Trinity Health Livonia, Livonia, USA.
Cureus
|November 29, 2023
概括
ангиотензин转化酶 (ACE) 抑制剂治疗可能导致罕见的血管. 这一案例突出显示,一名患者因利西诺普里尔诱导的血管而出现腹部症状,在药物停用后消失.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 内部医学 内部医学
背景情况:
- ангиотензин转化酶 (ACE) 抑制剂通常用于高血压和糖尿病.
- 由ACE抑制剂诱导的血管腺是一种罕见但严重的不良反应,通常表现为口腔大或周围轨道胀.
- 腹腔动脉瘤是ACE抑制剂治疗的一个不常见的表现.
研究的目的:
- 报告一个罕见的腹部血管发作病例,这是利西诺普里尔使用的次要原因.
- 突出胃肠道血管的诊断挑战和临床表现.
- 强调在复发的腹部症状中考虑药物副作用的重要性.
主要方法:
- 一个58岁的患有2型糖尿病和高血压的女性在lysinopril的病例报告.
- 对临床病史,症状 (腹痛,恶心,吐) 和诊断成像 (CT扫描) 的审查.
- 临床评估和患者在药物从利西诺普里尔转换为阿姆洛迪平后的结果.
主要成果:
- 患者出现了反复出现的胃肠道症状,暗示有血管.
- CT扫描显示了近邻小肠的一致发现.
- 停用利西诺普里尔并替换为安洛迪平导致症状完全消失.
结论:
- 由ACE抑制剂诱导的血管可以表现为腹部症状,模仿其他胃肠道疾病.
- 迅速识别和撤销侵权剂对于管理ACE抑制剂诱导的血管至关重要.
- 这一案例强调了对患者进行全面的药物评估的重要性,这些患者有不明原因的复发性腹部病情.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
654
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
654
Antihypertensive Drugs: Direct Renin Inhibitors
637
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
637
Antihypertensive Drugs: Angiotensin II Receptor Blockers
748
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
748
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs for Treatment of Constipation-Predominant IBS
179
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
179


